Patent · US Active

ABHD5 and partial HDAC4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases

US11312943B2 · kind B2 · utility

0Cited by

1References

7Claims

0Family size

Assignee

RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

Johannes Backs · Dallas, US
Zegeye Jebessa · Heidelberg, DE
Lorenz Lehmann · Gonterskirchen, DE
Hugo Katus · Heidelberg, DE
Oliver Müller · Dossenheim, DE

Key dates

Filing date	Jan 29, 2018
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Jan 29, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to Abhydrolase containing domain 5 (ABHD5) and N-terminal fragments of HDAC4 (HDAC4-NT) and variants of the aforementioned peptides for the treatment and prevention of heart failure. The present invention further provides vectors for the cardiomyocyte-specific expression of said peptides and a test system comprising ABHD5 for the identification of novel compounds which are useful for the treatment of heart failure.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.